5-Fluorouracil: mechanisms of action and clinical strategies
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU exerts its anti-cancer effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA [4].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“5-FU mainly destroys the deoxynucleotide pool required for DNA replication by inhibiting thymidylate synthase (TS), and mixes its metabolites into RNA and DNA to exert anti-tumor effects [4,127].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment”
From Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress (2014) · cites this paper as [210]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“Irinotecan is a topoisomerase I inhibitor and is active in the first- and second-line treatment of advanced colorectal cancer, in which it has shown improved survival and quality of life when compared with best supportive care in patients who have failed 5-FU/L”
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Research works printed but not linked: 2
- Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C14 by pre–neoplastic rat liver. Cancer Res. 14, 119 (1954).
- Jackson, R. C. & Grindley, G. B. The Biochemical Basis for Methotrexate Cytotoxicity (eds Sirotnak, F. M., Burchall, J. J., Ensminger, W. D. & Montgomery, J. A.) 289–315 (Academic, New York, 1984).
Cited by
Items 1,001–1,028 of 1,028
Hamaguchi, J., Nakagawa, H., Takahashi, M., Kudo, T., Kamiyama, N., Sun, B., Oshima, T., Sato, Y., Deguchi, K., Todo, S., et al. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-58 · Cited by 45
“5-FU affects the synthesis and repair of DNA and RNA processing in cancer cells [2-4].”
An epigenetic mechanism for capecitabine resistance in mesothelioma
Kosuri, K. V., Wu, X., Wang, L., Villalona-Calero, M. A., & Otterson, G. A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.095 · Cited by 44
“5-FU, a fluoropyrimidine, is an analogue of uracil which is converted intracellularly to FdUMP, FdUTP, and FUTP [16].”
BackgroundZhang, X., & Yang, S.-T. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.11.012 · Cited by 43
Li, Z., Chan, K., Qi, Y., Lu, L., Ning, F., Wu, M., Wang, H., Wang, Y., Cai, S., & Du, J. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.356 · Cited by 43
Specialized Ribosomes in Health and Disease
Miller, S. C., MacDonald, C. C., Kellogg, M. K., Karamysheva, Z. N., & Karamyshev, A. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076334 · Cited by 42
Welbat, J. U., Chaisawang, P., Pannangrong, W., & Wigmore, P. (2018) · Nutrients · doi:10.3390/nu10081053 · Cited by 42
“thymidylate synthase, which is important for DNA replication [14,15].”
BackgroundHyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
Pan, D. C., Krishnan, V., Salinas, A. K., Kim, J., Sun, T., Ravid, S., Peng, K., Wu, D., Nurunnabi, M., Nelson, J. A., et al. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10166 · Cited by 42
“are frequently used in chemotherapeutic treatment of gastrointestinal (GI) cancers, including colorectal cancer.(3-19) In most cases, two or more of these drugs are combined, resulting in greater efficacy.”
BackgroundLiu, T., Wang, X., Hu, W., Fang, Z., Jin, Y., Fang, X., & Miao, Q. R. (2019) · Neoplasia · doi:10.1016/j.neo.2019.03.011 · Cited by 41
Coupling of the radiosensitivity of melanocyte stem cells to their dormancy during the hair cycle
Ueno, M., Aoto, T., Mohri, Y., Yokozeki, H., & Nishimura, E. K. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12251 · Cited by 39
“Dct-lacZ tg mice (gift from Ian Jackson, MRC; Mackenzie et al., 1997; Nishimura et al., 2002) and MITF-ce mice (gift from Lynn Lamoreux; Zimring et al., 1996) were crossed with Dct-H2B-GFP tg mice, as previously described (Inomata et al., 2009; Nishimura et al., 2005).”
(2003) · PubMed · Cited by 36
Tan, Y., Zhang, S., Zhu, H., Chu, Y., Zhou, H., Liu, D., & Huo, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.48 · Cited by 35
“However, many CRC patients may develop resistance to 5-Fu during treatment, which is associated with a high rate of recurrence and poor survival (4).”
BackgroundDesprés, P. C., Cisneros, A. F., Alexander, E. M. M., Sonigara, R., Gagné-Thivierge, C., Dubé, A. K., & Landry, C. R. (2022) · Nature Ecology & Evolution · doi:10.1038/s41559-022-01846-4 · Cited by 32
The Synergistic Effect of 5-Aza-2′-Deoxycytidine and 5-Fluorouracil on Drug-Resistant Tumors
Morita, S., Iida, S., Kato, K., Takagi, Y., Uetake, H., & Sugihara, K. (2006) · Oncology · doi:10.1159/000107110 · Cited by 29
MiR‐129‐5p promotes docetaxel resistance in prostate cancer by down‐regulating CAMK2N1 expression
Wu, C., Miao, C., Tang, Q., Zhou, X., Xi, P., Chang, P., Hua, L., & Ni, H. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14050 · Cited by 28
“rouracil acts as thymidylate synthase inhibitor blocking synthesis of the pyrimidine thymidine which is required for DNA replication.(26,27) Therefore, the promoting function of miR‐129 in chemoresistance could be highly drug‐specific, which needs further studies.”
BackgroundEpigenetic reversal of acquired resistance to 5-fluorouracil treatment
Humeniuk, R., Mishra, P. J., Bertino, J. R., & Banerjee, D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0717 · Cited by 28
“Interestingly, IFN-g has been shown to up-regulate the activities of the 5-FU anabolic enzyme thymidine phosphorylase and uridine phosphorylase resulting in enhanced 5-FU activation (36).”
BackgroundMethodA narrative review of genetic factors affecting fluoropyrimidine toxicity
Gmeiner, W. H. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-21-17 · Cited by 25
“While the anti-cancer activities of FPs result primarily from conversion to FdUMP and inhibition of TS (2,37), up to 90% of 5-FU is degraded (38).”
BackgroundMin, D.-J., Vural, S., & Krushkal, J. (2019) · Cancer Genetics · doi:10.1016/j.cancergen.2019.05.005 · Cited by 23
Zargar, P., Ghani, E., Mashayekhi, F., Ramezani, A., & Eftekhar, E. (2018) · Oncology Letters · doi:10.3892/ol.2018.8569 · Cited by 23
Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice
Hammoud, R., Kaur, K. D., Koehler, J. A., Baggio, L. L., Wong, C. K., Advani, K. E., Yusta, B., Efimova, I., Gribble, F. M., Reimann, F., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174825 · Cited by 24
“…in mice treated with 5-fluorouracil (5FU) (12), a widely used chemotherapeutic agent that disrupts DNA synthesis through the inhibition of thymidylate synthase, leading to reduced cellular replication and apoptosis, often associated with intestinal injury, diarrhea, and intestinal mucositis (20).”
Notch receptor/ligand diversity: contribution to colorectal cancer stem cell heterogeneity
Brisset, M., Mehlen, P., Meurette, O., & Hollande, F. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1231416 · Cited by 20
Norouz Dolatabadi, E., Asghariazar, V., Darvish, M., & Nejati-Koshki, K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.104104 · Cited by 19
DNA Repair Capacity and Response to Treatment of Colon Cancer
Vodicka, P., Vodenkova, S., Buchler, T., & Vodickova, L. (2019) · Pharmacogenomics · doi:10.2217/pgs-2019-0070 · Cited by 19
Wang, J., Zhang, X., Zhang, J., Chen, S., Zhu, J., & Wang, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02353-5 · Cited by 18
“In addition, the incorporation of 5-FU-derived nucleosides into RNA fractions interferes with RNA synthesis and function [5].”
BackgroundHe, J., Xue, W., & Li, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s560983 · Cited by 16
“35 As noted above, dense ECM, elevated tumor interstitial pressure and abnormal vascular perfusion within the TME jointly restrict the effective intratumoral distribution of drugs, so that simply escalating the dose rarely yields a proportional increase in therapeutic efficacy.”
Zhang, H., Mu, Y., Han, C., & Zhou, Y. (2025) · Small · doi:10.1002/smll.202412303 · Cited by 14
Cross-feeding affects the target of resistance evolution to an antifungal drug
Durand, R., Jalbert-Ross, J., Fijarczyk, A., Dubé, A. K., & Landry, C. R. (2023) · PLOS Genetics · doi:10.1371/journal.pgen.1011002 · Cited by 14
“Rhodamine is a known substrate of ABC transporters and its accumulation in cells has been shown to be inversely correlated with efflux capacity (Maesaki et al. 1999).”
BackgroundRecruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6
“The most common therapeutic agent for CRC is 5-fluorouracil (5-FU), a thymidylate synthase inhibitor, which converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), causing DNA damage [15].”
BackgroundTargeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis
Xing, Z., Ma, Y., Jiang, X., Qing, H., Wu, Y., Che, S., Gao, Z., Wang, K., Wang, T., He, Q., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02557-5 · Cited by 4
“…(5-FU) is the cornerstone of the therapeutic protocol, and 5-FU-based FOLFIRINOX is recommended for patients with PC after surgery [3] 0.5-FU, a cell cycle-specific uracil analog, interacts with DNA,RNA, or both, leading to its accumulation in cells, and causing tumor cell damage and death [4].”
Influential
Metadata
- Authors
- Longley, D. B., Harkin, D. P., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Johnston, Patrick G.
- ORCID
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 330-338
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984328540
- Cited by
- 5,332
- References
- 111
- Citations by year
- 2026: 293 · 2025: 350 · 2024: 391 · 2023: 377 · 2022: 435 · 2021: 398 · 2020: 408 · 2019: 324 · 2018: 299 · 2017: 289 · 2016: 257 · 2015: 251 · 2014: 221 · 2013: 193 · 2012: 154
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- 5-fluorouracil, mechanism of action, drug resistance, predictive biomarkers, chemotherapeutic target, anticancer activity, cancer chemotherapy
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Fluorouracil, Humans, Interferons, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Biomarkers, Tumor Suppressor Protein p53, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.